Artículos de revistas
Antiplatelet activity and TNF-α release inhibition of phthalimide derivatives useful to treat sickle cell anemia
Fecha
2019-08-01Registro en:
Medicinal Chemistry Research, v. 28, n. 8, p. 1264-1271, 2019.
1554-8120
1054-2523
10.1007/s00044-019-02371-z
2-s2.0-85066493009
9734333607975413
0000-0003-4141-0455
Autor
Universidade Estadual Paulista (Unesp)
Universidade Estadual de Campinas (UNICAMP)
Institución
Resumen
Sickle Cell Anemia (SCA) is one of the most prevalent hereditary hematological diseases worldwide. The disease is characterized by chronic inflammation, hypercoagulable state, and pro-thrombotic profile, which lead the vaso-occlusive process. In this work, we described the antiplatelet activity and the ability to reduce tumor necrosis factor-alpha (TNF-α) levels of phthalimide derivatives. All compounds inhibited platelet aggregation induced by collagen and adenosine diphosphate, at levels ranging from 26.0 to 74.2% and 30.7 to 79.6%, respectively. The compounds exhibited reduced bleeding time compared to acetylsalicylic acid (ASA). Moreover, compounds 4c and 10c inhibited TNF-α levels at 73.5% and 65.0%, respectively. These findings suggest that phthalimide derivatives 4c and 10c are promising lead compounds useful to prevent vaso-occlusion and inflammation associated with the sickle cell anemia.